<DOC>
	<DOCNO>NCT01988103</DOCNO>
	<brief_summary>This study test clinical effectiveness safety two orally administer dos apremilast compare placebo Japanese patient moderate-to-severe plaque-type psoriasis . Apremilast ( CC-10004 ) new oral agent clinical development treatment inflammatory autoimmune disorder psoriasis , psoriatic arthritis , ankylose spondylitis , rheumatoid arthritis , Behçet disease .</brief_summary>
	<brief_title>Efficacy Safety Study Two Doses Apremilast ( CC-10004 ) In Japanese Subjects With Moderate-To-Severe Plaque-Type Psoriasis</brief_title>
	<detailed_description>This phase 2b , multicenter , randomize , double-blind , placebo-controlled study efficacy safety apremilast 20 mg twice day ( BID ) , apremilast 30 mg BID , placebo Japanese subject moderate severe plaque psoriasis .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Apremilast</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Male female Japanese subject great equal 20 year age . Diagnosis chronic , stable plaque psoriasis least 6 month prior screen define : PASI score ≥ 12 BSA ≥ 10 % . Psoriasis consider inappropriate topical therapy ( base severity disease extent affect area ) adequately control treated topical therapy spite least 4 week prior therapy least one topical medication psoriasis per label . In otherwise good health base medical history , physical examination , 12lead ECG , serum chemistry , hematology , immunology , urinalysis . Other psoriasis , history clinically significant uncontrolled systemic disease ; condition , include presence laboratory abnormality , would place subject unacceptable risk confound ability interpret data study . Prior medical history suicide attempt major psychiatric illness require hospitalization within last 3 year Pregnant breastfeeding . History ongoing chronic recurrent infectious disease . Active tuberculosis ( TB ) history incompletely treat TB . Clinically significant abnormality 12lead ECG chest radiograph screen . History human immunodeficiency virus ( HIV ) infection congenital acquire immunodeficiency ( eg , Common Variable Immunodeficiency ) . Hepatitis B surface antigen hepatitis B core antibody positive screening ; positive antibody hepatitis C screening . Malignancy history malignancy , except treat ( ie , cure ) basal cell squamous cell situ skin carcinoma treat ( ie , cure ) cervical intraepithelial neoplasia ( CIN ) carcinoma situ cervix evidence recurrence within previous 5 year . Psoriasis flare within 4 week screen . Topical therapy within 2 week prior randomization systemic therapy psoriasis psoriatic arthritis within 4 week prior randomization . Use etretinate within 2 year prior randomization female child bear potential ( FCBP ) within 6 month male , within 4 week prior randomization nonFCBP . Use phototherapy ( ie , UVB , PUVA ) within 4 week prior randomization prolong sun exposure use tan booths ultraviolet light source . Use adalimumab , etanercept , certolizumab pegol , abatacept , tocilizumab , golimumab infliximab within 12 week prior randomization ; use ustekinumab , alefacept briakinumab within 24 week prior randomization . Any investigational drug within 4 week prior randomization .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Psoriasis ; Psoriatic Arthritis</keyword>
</DOC>